Enhancer provides a potential target for ‘undruggable’ MYC in pediatric medulloblastoma
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 15:15 ET (22-Jun-2026 19:15 GMT/UTC)
A tumor-specific enhancer on extrachromosomal DNA drives MYC expression, revealing a new therapeutic target in high-risk pediatric medulloblastoma.
Wayne State University and the Barbara Ann Karmanos Cancer Institute researchers have secured a substantial grant from the American Cancer Society (ACS) to establish the Digital Engagement and Cancer Outcomes (DECO) Center. The center’s goals are to better understand the impact of the digital environment and digital inclusion on outcomes and disparities among Black cancer patients, survivors and caregivers, and advance interventions that both integrate and impact hospital and community resources to improve outcomes at the individual level.
• Cells constantly search for physical cues that guide their behavior yet respond biochemically.
How a cell converts mechanical information into a molecular process is a long-standing mystery of cell biology. By creating the first snapshot of a mechanical signaling complex in action, researchers have illuminated the steps between physical force and chemical response. The findings may illuminate disorders connected to myosin dysfunction, including cancers such as glioblastoma.
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause kidney-related immune complications in some patients, sometimes requiring therapy to be paused or stopped. A study led by Dr. Sandra Herrmann at Mayo Clinic sheds light on how this inflammation develops and offers early evidence for a targeted approach to better manage—and potentially prevent—these side effects.